ARTICLE | Finance
Connecting Epizyme's DOTs
Shards of dosing data may be behind volatility for Epizyme shares
January 13, 2014 8:00 AM UTC
Epizyme Inc. (NASDAQ:EPZM) has endured major ups and downs over the last couple of months on Phase I leukemia data as investors make bets for and against the stock on very little clinical data.
Epizyme's first look at Phase I data on Nov. 14, 2013, showed its EPZ-5676 next-generation epigenetics compound had not produced any objective responses in eight heavily pretreated leukemia patients with MLL gene rearrangements. EPZ-5676 is a histone methyltransferase DOT1L (DOT1L) inhibitor...